TRCT
SRNE

Tower Research Capital (TRC)’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Tower Research Capital (TRC)’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,316
Closed -$3K – 6645
2023
Q1 		$3K Sell
8,316
-5,176
-38% -$4.64K ﹤0.01% 5296
2022
Q4 		$11K Sell
13,492
-196,400
-94% -$261K ﹤0.01% 3932
2022
Q3 		$330K Buy
209,892
+134,712
+179% +$306K 0.01% 1468
2022
Q2 		$151K Sell
75,180
-48,986
-39% -$84.7K ﹤0.01% 1994
2022
Q1 		$289K Buy
124,166
+86,494
+230% +$270K ﹤0.01% 1492
2021
Q4 		$175K Sell
37,672
-47,072
-56% -$292K ﹤0.01% 1872
2021
Q3 		$647K Buy
84,744
+77,495
+1,069% +$657K 0.02% 805
2021
Q2 		$70K Sell
7,249
-42,706
-85% -$340K ﹤0.01% 2741
2021
Q1 		$413K Buy
49,955
+42,957
+614% +$454K 0.01% 1396
2020
Q4 		$47K Sell
6,998
-269,716
-97% -$2.17M ﹤0.01% 3187
2020
Q3 		$3.09M Buy
276,714
+189,302
+217% +$1.73M 0.03% 187
2020
Q2 		$549K Buy
+87,412
New +$335K 0.02% 940
2020
Q1 		– Sell
-97
Closed – – 4194
2019
Q4 		$0 Sell
97
-13,803
-99% -$32.9K ﹤0.01% 4636
2019
Q3 		$30K Buy
13,900
+13,612
+4,726% +$31.7K ﹤0.01% 2199
2019
Q2 		$1K Buy
288
+188
+188% +$677 ﹤0.01% 3528
2019
Q1 		$0 Buy
+100
New +$262 ﹤0.01% 4479
2018
Q4 		– Sell
-20,749
Closed -$91K – 4531
2018
Q3 		$91K Buy
+20,749
New +$115K 0.01% 1410
2018
Q2 		– Sell
-100
Closed -$1K – 4218
2018
Q1 		$1K Buy
+100
New +$711 ﹤0.01% 3128
2017
Q4 		– Sell
-2,872
Closed -$5K – 4193
2017
Q3 		$5K Sell
2,872
-4,724
-62% -$8.67K ﹤0.01% 3345
2017
Q2 		$15K Buy
7,596
+6,885
+968% +$13.4K ﹤0.01% 1387
2017
Q1 		$3K Sell
711
-184
-21% -$923 ﹤0.01% 2521
2016
Q4 		$4K Buy
895
+890
+17,800% +$5.35K ﹤0.01% 3184
2016
Q3 		$0 Buy
+5
New +$34 ﹤0.01% 4700
2016
Q2 		– Sell
-3,485
Closed -$19K – 5165
2016
Q1 		$19K Buy
3,485
+2,815
+420% +$16.4K ﹤0.01% 1396
2015
Q4 		$6K Buy
670
+470
+235% +$3.96K ﹤0.01% 2852
2015
Q3 		$2K Sell
200
-2,269
-92% -$36.1K ﹤0.01% 3441
2015
Q2 		$44K Buy
2,469
+29
+1% +$373 ﹤0.01% 1475
2015
Q1 		$28K Buy
+2,440
New +$28.2K ﹤0.01% 1981
2014
Q4 		– Sell
-450
Closed -$2K – 4885
2014
Q3 		$2K Sell
450
-369
-45% -$1.98K ﹤0.01% 3907
2014
Q2 		$6K Sell
819
-1,287
-61% -$9.71K ﹤0.01% 2764
2014
Q1 		$27K Buy
+2,106
New +$23.3K ﹤0.01% 1617

Other funds holding SRNE

SW
SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
OAJ
Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.68B AUM
CFGS
Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Tower Research Capital (TRC)'s SRNE Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 8,316 shares — an estimated $3K sold.

Tower Research Capital (TRC) first reported a position in SRNE in Q1 2014 and held it in 31 quarters. The position peaked at $3.09M in Q3 2020. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • Tower Research Capital (TRC) reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 8,316 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $3K.
  • Tower Research Capital (TRC) first reported a position in Sorrento Therapeutics, Inc. in Q1 2014 and held it in 31 quarters.
  • Tower Research Capital (TRC)'s Sorrento Therapeutics, Inc. position peaked at $3.09M in Q3 2020.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.